For HCC - and potentially even for metastatic liver disease... the biggest risk in the future to SRX is OSL, in view of the method of administration. The OSL patent allows for Yittrium to be incorporated but from memory only with P32.
Percutaneous administration is advantageous, but SRX is still years ahead of OSL.
For HCC - and potentially even for metastatic liver disease......
Add to My Watchlist
What is My Watchlist?